| Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease (NCT07661056) | Biohaven Therapeutics Ltd. | 2026-06-26 |
| A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy (NCT07642050) | Biohaven Therapeutics Ltd. | 2026-06-01 |
| Taldefgrobep Alfa in Adults With Overweight and Obesity (NCT07281495) | Biohaven Therapeutics Ltd. | 2025-11-24 |
| Study of BHV-1300 in Graves' Disease (NCT06980649) | Biohaven Therapeutics Ltd. | 2025-08-21 |
| Study of BHV-1400 in IgA Nephropathy (NCT07054684) | Biohaven Therapeutics Ltd. | 2025-07-30 |
| A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease (NCT06976268) | Biohaven Therapeutics Ltd. | 2025-05-28 |
| A Phase 1 Study of BHV-1530 in Advanced Solid Tumors (NCT06874335) | Biohaven Therapeutics Ltd. | 2025-03-20 |
| Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD) (NCT06423781) | Biohaven Therapeutics Ltd. | 2024-08-01 |
| Long-term Safety and Tolerability of BHV-7000 (NCT06443463) | Biohaven Therapeutics Ltd. | 2024-07-30 |
| BHV-7000 Open-Label Extension Bipolar Mania Study (NCT06423794) | Biohaven Therapeutics Ltd. | 2024-06-24 |
| A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures (NCT06425159) | Biohaven Therapeutics Ltd. | 2024-06-20 |
| BHV-7000 Acute Treatment of Bipolar Mania (NCT06419582) | Biohaven Therapeutics Ltd. | 2024-05-28 |
| Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression (NCT06419608) | Biohaven Therapeutics Ltd. | 2024-05-28 |
| Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy (NCT06309966) | Biohaven Therapeutics Ltd. | 2024-05-13 |
| A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors (NCT06384807) | Biohaven Therapeutics Ltd. | 2024-04-22 |
| A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy (NCT06132893) | Biohaven Therapeutics Ltd. | 2024-03-14 |
| Real-World Data Study of Troriluzole-Treated Patients With Spinocerebellar Ataxia (SCA) Compared to a Matched Natural History Control (NCT06529146) | Biohaven Therapeutics Ltd. | 2019-03-18 |